Skip to main content
Premium Trial:

Request an Annual Quote

Boston Strategics, Molecular Response Ink Deal to Improve Oncology Rx Trial Success

NEW YORK (GenomeWeb) – Therapeutic research firm Boston Strategics and molecular diagnostic services shop Molecular Response have agreed to design and manage drug development programs together with the aim of identifying subpopulations of best responders to treatments and improving their probability of success through clinical trials.

The companies will identify best responder sub-populations using patient-derived tumor xenograft models, genomic profiling technologies, and Molecular Response's proprietary bank of tumor cells. The bank contains 144,000 cryopreserved specimens from common and rare tumor types collected from the US population over two decades.

In turn, Boston Strategics will contribute its oncology drug development expertise. Through this deal, Molecular Response will become a member of Boston Strategics' 'True' Open Innovation platform, which fosters collaborations with providers of innovative resources in oncology drug development research.

Recently, Molecular Response announced it had opened a CLIA-certified, purpose-built facility in San Diego for providing clinical trial support services to pharmaceutical partners.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more